Precision medicine

From pharmacogenomics to pharmacoproteomics

Allison B. Chambliss, Daniel Wan-Yui Chan

Research output: Contribution to journalReview article

Abstract

Disease progression and drug response may vary significantly from patient to patient. Fortunately, the rapid development of high-throughput 'omics' technologies has allowed for the identification of potential biomarkers that may aid in the understanding of the heterogeneities in disease development and treatment outcomes. However, mechanistic gaps remain when the genome or the proteome are investigated independently in response to drug treatment. In this article, we discuss the current status of pharmacogenomics in precision medicine and highlight the needs for concordant analysis at the proteome and metabolome levels via the more recently-evolved fields of pharmacoproteomics, toxicoproteomics, and pharmacometabolomics. Integrated 'omics' investigations will be critical in piecing together targetable mechanisms of action for both drug development and monitoring of therapy in order to fully apply precision medicine to the clinic.

Original languageEnglish (US)
Article number25
JournalClinical Proteomics
Volume13
Issue number1
DOIs
StatePublished - Sep 26 2016

Fingerprint

Precision Medicine
Pharmacogenetics
Proteome
Medicine
Drug therapy
Metabolome
Drug Monitoring
Biomarkers
Pharmaceutical Preparations
Disease Progression
Genes
Throughput
Genome
Technology
Monitoring
Therapeutics

Keywords

  • Biomarker
  • Pharmacogenomics
  • Precision medicine
  • Proteomics

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry

Cite this

Precision medicine : From pharmacogenomics to pharmacoproteomics. / Chambliss, Allison B.; Chan, Daniel Wan-Yui.

In: Clinical Proteomics, Vol. 13, No. 1, 25, 26.09.2016.

Research output: Contribution to journalReview article

@article{1616b735e35241c88d33a43bbe583ae8,
title = "Precision medicine: From pharmacogenomics to pharmacoproteomics",
abstract = "Disease progression and drug response may vary significantly from patient to patient. Fortunately, the rapid development of high-throughput 'omics' technologies has allowed for the identification of potential biomarkers that may aid in the understanding of the heterogeneities in disease development and treatment outcomes. However, mechanistic gaps remain when the genome or the proteome are investigated independently in response to drug treatment. In this article, we discuss the current status of pharmacogenomics in precision medicine and highlight the needs for concordant analysis at the proteome and metabolome levels via the more recently-evolved fields of pharmacoproteomics, toxicoproteomics, and pharmacometabolomics. Integrated 'omics' investigations will be critical in piecing together targetable mechanisms of action for both drug development and monitoring of therapy in order to fully apply precision medicine to the clinic.",
keywords = "Biomarker, Pharmacogenomics, Precision medicine, Proteomics",
author = "Chambliss, {Allison B.} and Chan, {Daniel Wan-Yui}",
year = "2016",
month = "9",
day = "26",
doi = "10.1186/s12014-016-9127-8",
language = "English (US)",
volume = "13",
journal = "Clinical Proteomics",
issn = "1542-6416",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Precision medicine

T2 - From pharmacogenomics to pharmacoproteomics

AU - Chambliss, Allison B.

AU - Chan, Daniel Wan-Yui

PY - 2016/9/26

Y1 - 2016/9/26

N2 - Disease progression and drug response may vary significantly from patient to patient. Fortunately, the rapid development of high-throughput 'omics' technologies has allowed for the identification of potential biomarkers that may aid in the understanding of the heterogeneities in disease development and treatment outcomes. However, mechanistic gaps remain when the genome or the proteome are investigated independently in response to drug treatment. In this article, we discuss the current status of pharmacogenomics in precision medicine and highlight the needs for concordant analysis at the proteome and metabolome levels via the more recently-evolved fields of pharmacoproteomics, toxicoproteomics, and pharmacometabolomics. Integrated 'omics' investigations will be critical in piecing together targetable mechanisms of action for both drug development and monitoring of therapy in order to fully apply precision medicine to the clinic.

AB - Disease progression and drug response may vary significantly from patient to patient. Fortunately, the rapid development of high-throughput 'omics' technologies has allowed for the identification of potential biomarkers that may aid in the understanding of the heterogeneities in disease development and treatment outcomes. However, mechanistic gaps remain when the genome or the proteome are investigated independently in response to drug treatment. In this article, we discuss the current status of pharmacogenomics in precision medicine and highlight the needs for concordant analysis at the proteome and metabolome levels via the more recently-evolved fields of pharmacoproteomics, toxicoproteomics, and pharmacometabolomics. Integrated 'omics' investigations will be critical in piecing together targetable mechanisms of action for both drug development and monitoring of therapy in order to fully apply precision medicine to the clinic.

KW - Biomarker

KW - Pharmacogenomics

KW - Precision medicine

KW - Proteomics

UR - http://www.scopus.com/inward/record.url?scp=84992213777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992213777&partnerID=8YFLogxK

U2 - 10.1186/s12014-016-9127-8

DO - 10.1186/s12014-016-9127-8

M3 - Review article

VL - 13

JO - Clinical Proteomics

JF - Clinical Proteomics

SN - 1542-6416

IS - 1

M1 - 25

ER -